Professor of Clinical Genetics, UCLA
Pathology
Dr. Wayne W. Grody, MD
Wayne Grody is an expert in the field of Pathology. He graduated from Baylor College of Medicine. He received 5 awards: "America's Top Doctors", "Top Doctors:LA Area", "America's Top Doctors for Cancer", "Top Doctors:Southern California" and "Whos Who in Medicine and Healthcare". Wayne Grody is a published physician. He has 75 papers published. The most current publication "An infant with MLH3 variants, FOXG1-duplication and multiple, benign cranial and spinal tumors: A clinical exome sequencing study." Dr. Wayne W. Grody accepts all Medicare patients.
Publications
- An infant with MLH3 variants, FOXG1-duplication and multiple, benign cranial and spinal tumors: A clinical exome sequencing study.
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the...
- De Novo Nonsense Mutations in KAT6A, a Lysine Acetyl-Transferase Gene, Cause a Syndrome Including Microcephaly and Global Developmental Delay.
- Instability of a dinucleotide repeat in the 3'-untranslated region (UTR) of the microsomal prostaglandin E synthase-1 (mPGES-1) gene in microsatellite instability-high...
- Clinical Exome Sequencing for Genetic Identification of Rare Mendelian Disorders.
- Exome sequencing in the clinical diagnosis of sporadic or familial cerebellar ataxia.
- Interpreting whole-genome sequencing.
- Assessing the necessity of confirmatory testing for exome-sequencing results in a clinical molecular diagnostic laboratory.
- Myocyte-Mediated Arginase Expression Controls Hyperargininemia but not Hyperammonemia in Arginase-Deficient Mice.
- Carrier screening for cystic fibrosis in the new era of medications that restore CFTR function.
- A Case of Mycosis Fungoides Transmitted From Donor to Recipient, and Review of Literature of T-Cell Malignancies After Transplantation.
- ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.
- Lethal phenotype in conditional late-onset arginase 1 deficiency in the mouse.
- The M694V mutation in Armenian-Americans: a 10-year retrospective study of MEFV mutation testing for familial Mediterranean fever at UCLA.
- Current landscape and new paradigms of proficiency testing and external quality assessment for molecular genetics.
- ACMG position statement on prenatal/preconception expanded carrier screening.
- AAV-based gene therapy prevents neuropathology and results in normal cognitive development in the hyperargininemic mouse.
- Deaf Genetic Testing and Psychological Well-Being in Deaf Adults.
- Opportunities and Challenges Associated with Clinical Diagnostic Genome Sequencing: A Report of the Association for Molecular Pathology.
- Long-term Survival of the Juvenile Lethal Arginase-deficient Mouse With AAV Gene Therapy.
- Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
- Targeted Massively Parallel Sequencing Provides Comprehensive Genetic Diagnosis for Patients with Disorders of Sex Development.
- Expanded carrier screening and the law of unintended consequences: From cystic fibrosis to fragile X.
- DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study.
- Diagnosis and management of familial Mediterranean fever: integrating medical genetics in a dedicated interdisciplinary clinic.
- Colchicine's other indication--effect of FDA action.
- An exon 1 deletion in OTC identified using chromosomal microarray analysis in a mother and her two affected deceased newborns: implications for the prenatal diagnosis ...
- Direct-to-consumer genotyping: are we ready for a brave new world?
- The fate of newborn screening blood spots.
- Arginine metabolism by macrophages promotes cardiac and muscle fibrosis in mdx muscular dystrophy.
- Deaf adults' reasons for genetic testing depend on cultural affiliation: results from a prospective, longitudinal genetic counseling and testing study.
- Development and characterization of reference materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 genetic testing.
- Should we be applying warfarin pharmacogenetics to clinical practice? No, not now.
- Short-term correction of arginase deficiency in a neonatal murine model with a helper-dependent adenoviral vector.
- A prospective, longitudinal study of the impact of GJB2/GJB6 genetic testing on the beliefs and attitudes of parents of deaf and hard-of-hearing infants.
- Cystic fibrosis testing comes of age.
- Keeping up with the next generation: massively parallel sequencing in clinical diagnostics.
- Disruption of arginase II alters prostate tumor formation in TRAMP mice.
- Infant hearing loss and connexin testing in a diverse population.
- New quality assurance standards for rare disease testing.
- Increased plasma and tissue guanidino compounds in a mouse model of hyperargininemia.
- Ethnic differences in parental perceptions of genetic testing for deaf infants.
- Contrasting features of urea cycle disorders in human patients and knockout mouse models.
- The Cystic Fibrosis mutation "arms race": when less is more.
- Polyamine homeostasis in arginase knockout mice.
- Sharing GJB2/GJB6 genetic test information with family members.
- Variable penetrance and expressivity of the splice altering 5T sequence in the cystic fibrosis gene.
- Testing and reporting ACMG cystic fibrosis mutation panel results.
- The clinical significance of circulating tumor cells in the peripheral blood.
- Ornithine deficiency in the arginase double knockout mouse.
- Monitoring standards for molecular genetic testing in the United Kingdom, the Netherlands, and Ireland.
- Prelingual siblings of children with GJB2 hearing loss: issues to consider.
- Developing a sustainable process to provide quality control materials for genetic testing.
- Technical standards and guidelines: venous thromboembolism (Factor V Leiden and prothrombin 20210G >A testing): a disease-specific supplement to the standards and g...
- A novel method for creating artificial mutant samples for performance evaluation and quality control in clinical molecular genetics.
- Risk calculations for cystic fibrosis in neonatal screening by immunoreactive trypsinogen and CFTR mutation tests.
- Genetic testing as part of the early hearing detection and intervention (EHDI) process.
- Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel.
- Cystic fibrosis mutation analysis: how many is enough?
- Bayesian analysis for cystic fibrosis risks in prenatal and carrier screening.
- Arginases I and II: do their functions overlap?
- Estimated analytic validity of HFE C282Y mutation testing in population screening: the potential value of confirmatory testing.
- Quest for controls in molecular genetics.
- Widespread expression of arginase I in mouse tissues. Biochemical and physiological implications.
- Alternative approaches to proficiency testing in molecular genetics.
- Cystic fibrosis mutations in Costa Rica.
- Ethical issues raised by genetic testing with oligonucleotide microarrays.
- Molecular genetic risk screening.
- Cystic fibrosis carrier screening: issues in implementation.
- Standards and guidelines for CFTR mutation testing.
- Mouse model for human arginase deficiency.
- Discordant pursuit asymmetry and esotropia in monozygous twins.
- Expression of the liver form of arginase in erythrocytes.
- Cloning and characterization of human agmatinase.
Schools
Baylor University
UCLA School Med
University Of California Los Angeles
UCLA Mc
Doctors Specialties
- Molecular Genetic Pathology
- Pathology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Select Plus HMO
- Select PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Culinary Health Fund
- First Health (Coventry Health Care) PPO
- Blue & Gold HMO
- Covered California - Bronze PPO
- Employer Group HMO
- Health Net PPO
- Individual and Family PPO
- Medicare MCR
- Heritage Signature
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- PacifiCare HMO
- United Healthcare
Awards
- America's Top Doctors
- Top Doctors:LA Area
- America's Top Doctors for Cancer
- Top Doctors:Southern California
- Whos Who in Medicine and Healthcare
Education
-
UCLA Medical Center -
Baylor College of Medicine
Hospital
-
Ronald Reagan UCLA Medical Center -
Santa Monica-UCLA Medical Center and Orthopaedic Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1235165796 |
| Last Name Of The Provider | GRODY |
| First Name Of The Provider | WAYNE |
| View All |
Similar Doctors
|
Dr. Walter F. Coulson, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Alexander N. Fedenko, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric Y. Loo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Beatrice S. Knudsen, MD |
|
|
Dr. Christie Pang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer J. Wei, MD |
|
|
Dr. David M. Parham III, MD
This Doctor is OpenDoctor Recommended.
|